pacritinib – Patient Worthy

Pacritinib Receives Accelerated Approval for Myelofibrosis With Severely Low Platelet Count

Post author:Rose Duesterwald
Post published:March 8, 2022
Post category:Myelofibrosis

Cancer Network recently featured a press release by CTI BioParma announcing that the FDA has given accelerated approval for pacritinib to treat patients diagnosed with myelofibrosis and severely low platelets…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More